Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay
Kwang-Hyun CHUNG; Won KIM; Byeong-Gwan KIM; Ho-Young LEE; Eunhyo JIN; Yuri CHO; Ji-Yeon SEO; Hwi-Young KIM; Yong-Jin JUNG; Ji-Won KIM; Ji-Bong JEONG; Kook-Lae LEE.
Gut and Liver
; : 657-664, 2015.
Artículo
en Inglés
| WPRIM | ID: wpr-216103
BACKGROUND/
AIMS:
Quantification of hepatitis B surface antigen (HBsAg) is an emerging serologic test and may be useful for identifying treatment strategies for chronic hepatitis B (CHB). This study aimed to evaluate HBsAg titers during the natural course of CHB and identify correlations between HBsAg titers and hepatitis B virus (HBV) DNA concentrations across different CHB phases measured using an immunoradiometric assay (IRMA).METHODS:
CHB phases were defined on the basis of HBV DNA concentrations, the presence of hepatitis B e antigen/antibody (HBeAg/Ab) and serum alanine aminotransferase levels. Serum HBsAg titers and paired HBV DNA concentrations in the different phases of CHB were compared using 627 serum samples.RESULTS:
Mean HBsAg titers were significantly higher in the immunotolerant (IT) phase and immunoreactive (IR) HBeAg-positive phase than in the low-replicative (LR) and HBeAg-negative CHB (ENH) states. The correlation between HBsAg titers and HBV DNA concentrations was modest in the IT (n=36, r=0.804, p<0.001) and IR (n=48, r=0.773, p<0.001) phases, and it was poor in the LR state (n=116, r=0.289, p=0.002); however, no significant correlation was observed in the ENH state (n=67, r=0.146, p=0.237) or in the oral nucleos(t)ide analogue-treated group (n=267).CONCLUSIONS:
HBsAg quantification using IRMA might be useful for discriminating different CHB phases and different stages of chronic liver disease.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados